Friday 14th November 2003
|Text too small?|
Basically, Blis is moving away from investing in research and development and needs cash to focus on rolling out its products internationally.
The trouble is local sales were unimpressive over the past six months and getting a start in the US and Asia typically is expensive.
Blis chief executive Kelvin Moffatt said the issue size came down to a trade off between R&D and getting existing products to market.
"The amount of cash we are raising reflects that point."
In other words the directors realise it is time to start making money.
Moffatt expressed disappointment at the company's domestic performance during the winter, with operating revenue dipping 10% to $269,000 in the six months to September.
"We probably rested on our laurels a bit ... but the New Zealand market was never going to be the answer to our income we need to look internationally."
Blis has three products on the go, including its flagship K12 bacterial throat protector, a tooth decay preventative and a halitosis preventative.
The company was targeting Asia for sore throat treatment and the US for its oral hygiene products.
Blis shares received a boost in September following a deal to register and sell K12 in China but have since dropped back to below 30c.
No comments yet
Further Contract Win Strengthens Scott Technology’s Position In Mining Sector
China’s Assertiveness Is Becoming a Problem for Its Friends, Too
New Talisman - Chairman’s Address to AGM 2020 August 6, 2020
T&G reports its 2020 Interim Results
Gold price hits $2,000 for first time on Covid
TruScreen strengthens its market presence in central and eastern Europe
Refining NZ announces non-cash impairment
Ryman Healthcare COVID-19 update Victoria
Talisman Quarterly Activities Report to 30 June 2020
General Capital gives notice of Annual Meeting